Branded

NEW YORK — "Fake drugs are a big threat and an exploding threat," Kumar Kibble, deputy director of Immigration and Customs Enforcement, told the news program "60 Minutes" in a segment that appeared Sunday night.

FOSTER CITY, Calif. — Drug maker Gilead acknowledged the receipt of an unsolicited mini-tender offer by TRC Capital.

Gilead said that TRC seeks to purchase up to 3 million shares of the company at a price of $37.25 per share, or about $111.75 million. The drug maker said it is recommending shareholders reject the bid, stating that the offer is priced below the current market price for Gilead shares and is subject to numerous conditions. As of March 2, TRC's offer price represented approximately a 4.56% discount to the $39.03 closing price of Gilead common stock.

WASHINGTON — By 2015, “pharmacists will be the healthcare professionals responsible for providing patient care that ensures optimal medication therapy outcomes.” That was the consensus reached in the Joint Commission of Pharmacy Practitioners' vision statement at the Pharmacy Technician Certification Board’s Consumer Awareness, Resources, Education, State Policy and Testing Summit last month.

DANBURY, Conn. — A drug maker focused on development and commercialization of diabetes treatments unveiled its accelerating clinical development plans of two drug candidates.

Biodel said BIOD-105 and BIOD-107, known as ultra rapid-acting insulins, are designed to result in more rapid insulin action, compared with currently marketed mealtime insulin analogs.

CAMBRIDGE, Mass. — A late-stage trial of a biologic treatment for Type 1 diabetes appears to have failed, according to results announced Friday.

SEATTLE — The Food and Drug Administration has approved biotech company Dendreon’s expansion of manufacturing capacity for an immunotherapy treatment for prostate cancer, Dendreon said Thursday.

The company said it would be able to increase the ability of Provenge (sipuleucel-T) manufactured at its plant in New Jersey by increasing the number of workstations to produce it from 12 to 48.

The treatment is designed to induce an immune response against prostatic acid phosphatase, an antigen present in most prostate cancers.

RESEARCH TRIANGLE PARK, N.C. — GlaxoSmithKline said it is establishing a dedicated team to support community pharmacists and other healthcare professionals.

Effective March 28, GSK said its community pharmacy liaisons will provide information and tools to help community pharmacists communicate with their patients about chronic diseases and the appropriate use of medicines and vaccines.

INDIANAPOLIS — Eli Lilly on Thursday announced that it has named Greg Plowman VP oncology research and SVP for ImClone Systems research.

Plowman will oversee the oncology research efforts of both Lilly and ImClone, the drug maker's subsidiary that it acquired in 2008. He will report to Jan Lundberg, EVP science and technology and Lilly Research Labs president, as well as Bernhard Ehmer, ImClone president.

Prior to accepting the position at Lilly, Plowman served as senior director of research for Genentech for six years. He officially will join the company March 28.